Differential effects of activation of liver X receptor on plasma lipid homeostasis in wild-type and lipoprotein clearance-deficient mice

Atherosclerosis

Volumn 208, Issue 1, 2010, Pages 126-133

  Peng, Dacheng ^a   Hiipakka, Richard A ^a   Xie, Jing Tian ^a   Reardon, Catherine A ^b   Getz, Godfrey S ^b   Liao, Shutsung ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Lipoprotein clearance deficiency; LPL; LXR; Triglycerides; VLDL

Indexed keywords

CHOLESTEROL; LIVER X RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR; N (2,2,2 TRIFLUOROETHYL) N [4 [2,2,2 TRIFLUORO 1 HYDROXY 1 (TRIFLUOROMETHOXY)ETHYL]PHENYL]BENZENESULFONAMIDE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG MECHANISM; DRUG RESPONSE; HYPERTRIGLYCERIDEMIA; LIPID METABOLISM; LIPOGENESIS; LIPOLYSIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL; WILD TYPE;

ANIMALS; HOMEOSTASIS; LIPIDS; LIPOPROTEINS; MALE; MICE; MICE, INBRED C57BL; ORPHAN NUCLEAR RECEPTORS; TRIGLYCERIDES;

EID: 73449114562     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.07.016     Document Type: Article

References (34)

1. Cao G., Liang Y., Jiang X.C., and Eacho P.I. Liver X receptors as potential therapeutic targets for multiple diseases. Drug News Perspect 17 (2004) 35-41
2. Repa J.J., Turley S.D., Lobaccaro J.A., et al. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science 289 (2000) 1524-1529
3. Wang N., Ranalletta M., Matsuura F., Peng F., and Tall A.R. LXR-induced redistribution of ABCG1 to plasma membrane in macrophages enhances cholesterol mass efflux to HDL. Arterioscler Thromb Vasc Biol 26 (2006) 1310-1316
4. Yancey P.G., Yu H., Linton M.F., and Fazio S. A pathway-dependent on apoE, ApoAI, and ABCA1 determines formation of buoyant high-density lipoprotein by macrophage foam cells. Arterioscler Thromb Vasc Biol 27 (2007) 1123-1131
5. Schultz J.R., Tu H., Luk A., et al. Role of LXRs in control of lipogenesis. Genes Dev 14 (2000) 2831-2838
6. Grefhorst A., Elzinga B.M., Voshol P.J., et al. Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles. J Biol Chem 277 (2002) 34182-34190
7. Zhang Y., Repa J.J., Gauthier K., and Mangelsdorf D.J. Regulation of lipoprotein lipase by the oxysterol receptors, LXRalpha and LXRbeta. J Biol Chem 276 (2001) 43018-43024
8. Cao G., Beyer T.P., Yang X.P., et al. Phospholipid transfer protein is regulated by liver X receptors in vivo. J Biol Chem 277 (2002) 39561-39565
9. Luo Y., and Tall A.R. Sterol upregulation of human CETP expression in vitro and in transgenic mice by an LXR element. J Clin Invest 105 (2000) 513-520
10. Repa J.J., Li H., Frank-Cannon T.C., et al. Liver X receptor activation enhances cholesterol loss from the brain, decreases neuroinflammation, and increases survival of the NPC1 mouse. J Neurosci 27 (2007) 14470-14480
11. Levin N., Bischoff E.D., Daige C.L., et al. Macrophage liver X receptor is required for antiatherogenic activity of LXR agonists. Arterioscler Thromb Vasc Biol 25 (2005) 135-142
12. Peng D., Hiipakka R.A., Reardon C.A., Getz G.S., and Liao S. Differential anti-atherosclerotic effects in the innominate artery and aortic sinus by the liver X receptor agonist T0901317. Atherosclerosis 203 (2009) 59-66
13. Terasaka N., Hiroshima A., Koieyama T., et al. T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice. FEBS Lett 536 (2003) 6-11
14. Joseph S.B., McKilligin E., Pei L., et al. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc Natl Acad Sci USA 99 (2002) 7604-7609
15. Peng D., Hiipakka R.A., Dai Q., et al. Antiatherosclerotic effects of a novel synthetic tissue-selective steroidal liver X receptor agonist in low-density lipoprotein receptor-deficient mice. J Pharmacol Exp Ther 327 (2008) 332-342
16. Cullen P. Evidence that triglycerides are an independent coronary heart disease risk factor. Am J Cardiol 86 (2000) 943-949
17. Bishop J.R., Stanford K.I., and Esko J.D. Heparan sulfate proteoglycans and triglyceride-rich lipoprotein metabolism. Curr Opin Lipidol 19 (2008) 307-313
18. Alexander C.M., Landsman P.B., Teutsch S.M., and Haffner S.M. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 52 (2003) 1210-1214
19. Gao Z.G., Choi H.G., Shin H.J., et al. Physicochemical characterization and evaluation of a microemulsion system for oral delivery of cyclosporine A. Int J Pharm 161 (1998) 75-86
20. Reardon C.A., Blachowicz L., White T., et al. Effect of immune deficiency on lipoproteins and atherosclerosis in male apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 21 (2001) 1011-1016
21. Bligh E.G., and Dyer W.J. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37 (1959) 911-917
22. Camps L., Reina M., Llobera M., et al. Lipoprotein lipase in lungs, spleen, and liver: synthesis and distribution. J Lipid Res 32 (1991) 1877-1888
23. Burgaya F., Peinado J., Vilaró S., Llobera M., and Ramírez I. Lipoprotein lipase activity in neonatal-rat liver cell types. Biochem J 259 (1989) 159-166
24. Mak P.A., Laffitte B.A., Desrumaux C., et al. Regulated expression of the apolipoprotein E/C-I/C-IV/C-II gene cluster in murine and human macrophages. A critical role for nuclear liver X receptors alpha and beta. J Biol Chem 277 (2002) 31900-31908
25. Havel R.J., Shore V.G., Shore B., and Bier D.M. Role of specific glycopeptides of human serum lipoproteins in the activation of lipoprotein lipase. Circ Res 27 (1970) 595-600
26. Shachter N.S., Hayek T., Leff T., et al. Overexpression of apolipoprotein CII causes hypertriglyceridemia in transgenic mice. J Clin Invest 93 (1994) 1683-1690
27. Berbee J.F.P., van der Hoogt C.C., Sundararaman D., Havekes L.M., and Rensen P.C.N. Severe hypertriglyceridemia in human APOC1 transgenic mice is caused by apoC-I-induced inhibition of LPL. J Lipid Res 46 (2005) 297-306
28. Westerterp M., de Haan W., Berbee J.F.P., Havekes L.M., and Rensen P.C.N. Endogenous apoC-I increases hyperlipidemia in apoE-knockout mice by stimulating VLDL production and inhibiting LPL. J Lipid Res 47 (2006) 1203-1211
29. Medh J.D., Fry G.L., Bowen S.L., et al. Lipoprotein lipase-and hepatic triglyceride lipase-promoted very low density lipoprotein degradation proceeds via an apolipoprotein E-dependent mechanism. J Lipid Res 41 (2000) 1858-1871
30. Jong M.C., Dahlmans V.E., Hofker M.H., and Havekes L.M. Nascent very-low-density lipoprotein triacylglycerol hydrolysis by lipoprotein lipase is inhibited by apolipoprotein E in a dose-dependent manner. Biochem J 328 (1997) 745-750
31. Inaba T., Matsuda M., Shimamura M., et al. Angiopoietin-like protein 3 mediates hypertriglyceridemia induced by the liver X receptor. J Biol Chem 278 (2003) 21344-21351
32. Williams S.E., Inoue I., Tran H., et al. The carboxyl-terminal domain of lipoprotein lipase binds to the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor (LRP) and mediates binding of normal very low density lipoproteins to LRP. J Biol Chem 269 (1994) 8653-8658
33. Levy E., Deckelbaum R.J., Thibault R.L., et al. In vitro remodelling of plasma lipoproteins in whole plasma by lipoprotein lipase in primary and secondary hypertriglyceridaemia. Eur J Clin Invest 20 (1990) 422-431
34. Vanderlaan P.A., Reardon C.A., Thisted R.A., and Getz G.S. VLDL best predicts aortic root atherosclerosis in LDL receptor deficient mice. J Lipid Res 50 (2008) 376-385